The size of the Europe microbiome sequencing services market was valued at USD 308 million in 2024. This market is expected to grow at a CAGR of 21.17% from 2025 to 2033 and be worth USD 1,734 million by 2033 from USD 373 million in 2025.
The examination of microbial groups found in and on the human body is known as microbiome sequencing. The purpose of human microbiome research is to learn more about how bacteria function in health and disease. Previously, analyzing samples from human skin, stool, or blood required time-consuming and labor-intensive microbiological methods such as cultivating and isolating individual organisms, then phenotypic or genotypic analysis. However, the introduction of NGS has enabled a slew of high-profile joint studies to publish a wealth of data on the human microbiome, with NGS serving as an essential tool.
The growing use of microbiomes in genomics, proteomics, and metabolomics, and mechanical advancements in cutting-edge sequencing are driving the market growth. The market is being fueled by the growing scale of pharmaceutical enterprises and growing awareness of the benefits of microbiome sequencing for cancer treatment.
The rise in chronic disease occurrences is having a substantial impact on market demand. In addition, the increasing biological research and development institutes, growing genomics studies, and rising regular diseases all contribute to the expansion of the microbiome sequencing services market.
Furthermore, rising healthcare spending in metropolitan areas and increased government support through investments drive demand for microbiome sequencing services. Also driving demand for the market is the growing importance of early diagnosis, as some diseases can be completely healed if caught early enough.
The government has strict laws and restrictions, and the cost of installing and maintaining the equipment is a little high. These factors are also predicted to limit the market for microbiome sequencing services. In addition, a market expansion might be hampered by a lack of innovation combined with extensive analysis. The market's growth rate is being slowed by fewer technicians, physicians, and scientists. The high cost of laboratory equipment is also hindering the growth of the microbiome sequencing services market. Factors such as the lack of proper rules and government directives are also impeding expansion.
REPORT METRIC |
DETAILS |
Market Size Available |
2024 to 2033 |
Base Year |
2024 |
Forecast Period |
2025 to 2033 |
Segments Covered |
By Technology, Application, Research Type, Laboratory Type, End User, and country. |
Various Analyses Covered |
Global, Regional and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Countries Covered |
UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, the Czech Republic, and the Rest of Europe |
Market Leaders Profiled |
Metabiomics Corp., Microbiome Therapeutics LLC, Microbiome Insights Inc., Rancho Biosciences, Zymo Research Corp., Molzym GmbH & Co., Ubiome Inc., Diversigen Inc., Merieux Nutrisciences Corporation, and Molecular Research LP. |
Geographically, Europe held the second-largest share of the Microbiome sequencing services market. However, with the rise in genetic illnesses, the European region is likely to demonstrate promising growth during the forecast period. In addition, self-medication is becoming more popular, driving the market's expansion. However, the increasing use of microbiomes in genomics, proteomics, and metabolomics is credited with the regional market growth. On the other hand, countries such as the United Kingdom, Germany, Spain, Italy, and France are expanding the European microbiome sequencing services market.
The UK Microbiome Sequencing Services Market and the Germany Microbiome Sequencing Services Market are witnessing a significant market share due to prominent companies, growing awareness of next-generation sequencing, and the availability of advanced healthcare infrastructure. In addition, the growing use of microbiomes in genomics, proteomics, and metabolomics, as well as advancements in technology in cutting-edge sequencing, are driving the European microbiome sequencing services market ahead.
Key players operating in the European microbiome sequencing services market profiled in this report are Metabiomics Corp., Microbiome Therapeutics LLC, Microbiome Insights Inc., Rancho Biosciences, Zymo Research Corp., Molzym GmbH & Co., Ubiome Inc., Diversigen Inc., Merieux Nutrisciences Corporation, and Molecular Research LP.
This Europe microbiome sequencing services market research report is segmented and sub-segmented into the following categories.
By Technology
By Application
By Research Type
By Laboratory Type
By End User
By Country
Frequently Asked Questions
The Europe microbiome sequencing services market is driven by increased demand for genomics research, rising chronic disease cases, technological advancements in NGS, and growing pharmaceutical and biological research investments.
The Europe microbiome sequencing services market faces challenges including high equipment costs, strict regulatory requirements, shortage of skilled professionals, and limited innovation in sequencing technologies.
Opportunities in the Europe microbiome sequencing services market include expanding applications in personalized medicine, increased government funding, and growing use of microbiome data in early disease diagnosis and drug development.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region